MMP9 and cancer: Results from clinical trials indicate that HIV-protease inhibitors are more efficacious in the early (premetastatic) stages of tumor progression [48,143,157,159]; this observation suggests that the HIV-protease inhibitors could be explored for metastases prevention in early-stage cancers overexpressing MMP-9.